Summary by Moomoo AI
Shanghai Microchong Medical Robots (Group) Co., Ltd. (“Micro-Chung Robots”) issued a voluntary announcement on March 5, 2024, predicting that its full-year revenue in 2023 will grow by more than 350% year-on-year. This significant growth was driven primarily by the commercialization of its flagship products, including the Tomei quad-arm laparoscopic surgical robot, the Hung Kung joint replacement surgical robot, and the Dragonfly Eye three-dimensional electronic laparoscopy process. The company also expects to record a net loss of no more than RMB1,050 million in 2023, down from 2022, mainly due to increased sales revenue and improved R&D efficiency. Despite the increase in sales expenses and one-time adjustment expenses, the company has made good progress in the commercialization of the domestic and...Show More